Richard Gomendoza, MD
Endocrinology, Diabetes & Metabolism · Salina, KSNPI 1841255734
Payments from drug & device makers
Across 743 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AbbVie$1K
- Sanofi-aventis U.S. LLC$943
- Corcept Therapeutics$739
- AstraZeneca$692
- plus $6K from 40 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,887 in reported general payments places this provider in the 75th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Salina
- Alan WynneTopeka$6.9M
- Susan BrianTopeka$2.8M
- Dany ZayourWichita$744K
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Rami MortadaWichita$105K
- Kristine GrdinovacKansas City$82K
- Sajeev MenonOverland Park$26K
- Leland GravesKansas City$23K
- Rudruidee KarnchanasornKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.